Inside healthcare's gig economy

Welcome to

Business Insider

’

s daily healthcare newsletter

, your daily dose of pharma, biotech, and healthcare news.

Subscribe here to get this newsletter in your inbox every weekday.

Pills 2 (2)Hollis Johnson/Business Insider

Hello,

Today in healthcare news: An inside look at Papa, a startup that’s tapping into the growing gig economy in healthcare, the limitations of what vaccine results can tell us about transmission, and a new approach to taking on the massive middlemen in the pharmacy industry.

Senior 02Courtesy of Papa; Yuqing Liu/Business Insider

Investors are betting big that Papa can succeed by applying Uber’s gig-work strategy to home care. We spoke to 9 ‘grandkids on demand’ for an inside look at the future of healthcare.



Read the full story from Megan Hernbroth>>

Moderna vaccineTaimy Alvarez/APUniversity of Miami Miller School of Medicine lab tech Sendy Puerto processes blood samples from study participants in the specimen processing lab, Wednesday, Sept. 2, 2020 in Miami. The volunteers are taking part in testing the NIH funded Moderna COVID-19 vaccine.

Moderna’s chief medical officer says that vaccine trial results only show that they prevent people from getting sick — not necessarily that recipients won’t still be able to transmit the virus

  • Moderna Chief Medical Officer Tal Zaks told Axios that the public should not “over-interpret” the vaccine trial results to assume life could go back to normal after adults are vaccinated.
  • “They do not show that they prevent you from potentially carrying this virus transiently and infecting others,” Zaks told Axios.
  • While he believes, based on the science, that it’s likely that vaccine does prevent transmission, but said there’s still no solid proof of that yet.
  • “I think it’s important that we don’t change behaviour solely on the basis of vaccination,” he said.


Read the full story from Sarah Al-Arshani here>>

Joe MuradWithMe HealthWithMe Health CEO Joe Murad.

Healthcare’s top VCs backed a startup’s unsuccessful attempt to unseat a massive part of the $US335 billion prescription-drug business. Now, WithMe is back with $US20 million with another approach to take on the industry.


Read the full story from Megan Hernbroth here>>

More stories we’re reading:

See you tomorrow for my last dispatch for the holiday week! Until then, be sure to subscribe here if you haven’t yet!

– Lydia

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.